MedTrace Logo

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

NCT07699952 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-08-17

No results posted yet for this study

Summary

To explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)

Conditions

  • Lung Cancer (NSCLC)
  • EGFR Activating Mutation
  • HER2

Interventions

DRUG

Almonertinib

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) options are permitted, with almonertinib mesylate selected as the first-line preference

DRUG

Trastuzumab Rezetecan

HER2 ADC

Sponsors & Collaborators

  • Yongsheng Wang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-09
Primary Completion
2029-03-31
Completion
2029-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07699952 on ClinicalTrials.gov